Renal Biomarkers Market Size, Share & Trends Analysis Report By Biomarkers (Functional Biomarkers, Upregulated Proteins), By Diagnostic Technique (ELISA, Immunoassays), By End Use (Hospitals & Clinics), By Region, And Segment Forecasts, 2025 - 2033

Renal Biomarkers Market Summary

The global renal biomarkers market size was estimated at USD 1,530.0 million in 2024 and is expected to reach USD 3,161.4 million by 2033, growing at a CAGR of 8.54% from 2025 to 2033. The rising prevalence of kidney disease particularly chronic kidney disease (CKD) and acute kidney injury (AKI) along with the urgent clinical need for earlier and more nuanced detection beyond conventional measures.

CKD often remains asymptomatic until advanced stages, and biomarkers that can reveal subclinical pathology or early injury are of growing interest. In the U.S., an estimated 35.5 million adults have chronic kidney disease (CKD), and a significant number are unaware of their condition. Globally, CKD affects around 850 million people, which is approximately 9% of the adult population. A 2024 study projects that by 2032, nearly 125 million people across eight major countries will have advanced CKD, a 25% increase since 2022. In April 2024, AstraZeneca’s IMPACT CKD modeling study projected that by 2032, as many as 16.5% of the population across eight countries could be affected by chronic kidney disease (CKD), with advanced-stage cases potentially increasing by up to 59.3%. The findings, presented at the 2024 ISN World Congress of Nephrology (WCN’24) in Buenos Aires, underscored the escalating global health challenge posed by CKD and emphasized its significant economic and environmental consequences. The large and growing base of kidney disease patients ensures a continually rising demand for more sensitive, specific, and multiplex biomarker assays. In addition, co-morbidities such as diabetes, hypertension, and aging populations further exacerbate kidney stress, pushing clinicians and payers to adopt advanced biomarkers (e.g. NGAL, KIM-1, cystatin C) earlier in the disease continuum to improve prognostics, therapy stratification, and monitoring. The high rate of undiagnosed early CKD (sometimes up to 90 % of cases go unnoticed until functional decline) underscores the latent market potential for tools that reliably flag early damage before conventional metrics (eGFR, creatinine) deviate significantly.

One of the most compelling opportunities in the renal biomarker landscape lies in emerging markets-Asia, Latin America, Africa where rising incidence of hypertension, diabetes, and aging populations is intensifying the renal disease burden, yet diagnostic infrastructure remains underdeveloped. As diagnostics penetration is still relatively low in many of these geographies, the entry of affordable, point-of-care biomarker platforms offers a high-growth niche. For example, Sphingotec’s collaborations (e.g. with Beckman Coulter) to release penKid assays on standard clinical lab platforms reflect how a biomarker originally confined to research can scale into broader clinical adoption. (See news of licensing and launch of penKid in central labs) The capacity to deploy multiplex panels, low-volume assays, or simpler rapid tests in decentralized settings could help bridge diagnostic gaps in underserved regions.

Meanwhile, platform diversity is growing enzyme-linked immunosorbent assays (ELISA) still command a significant share, but more sensitive chemiluminescent immunoassays, multiplex panels, mass spectrometry (LC-MS), microfluidics, and point-of-care immunodiagnostic devices are gaining traction. For instance, the penKid assay’s adoption on Beckman Coulter immunoassay platforms exemplifies how a novel biomarker can be integrated lab workflows. In research settings, microfluidic and multi-omics platforms will support novel discovery and multiplex panels opening scope for biomarker companies to offer value-added analytics, software, and interpretation services.

Global Renal Biomarkers Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global renal biomarkers market based on biomarker, diagnostic technique, end use, and region:

• Biomarkers Outlook (Revenue, USD Million, 2021 - 2033)
• Kits and reagents
• Functional Biomarkers
• Serum Creatinine
• Blood Urea Nitrogen (BUN)
• Estimated Glomerular Filtration Rate (eGFR)
• Upregulated Proteins
• Kidney Injury Molecule-1 (KIM-1)
• Neutrophil Gelatinase-Associated Lipocalin (NGAL)
• Cystatin C
• Interleukin-18 (IL-18)
• Others
• Other Novel Biomarkers
• microRNA biomarkers
• Proteomic/metabolomic markers
• Diagnostic technique/Platform Outlook (Revenue, USD Million, 2021 - 2033)
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Immunoassays
• Clinical Chemistry Assays
• Point-of-Care Testing (POCT) Devices
• Molecular Diagnostics
• Other Emerging Platforms
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Clinics
• Diagnostic Laboratories
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
• U.S.
• Canada
• Mexico
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Thailand
• Latin America
• Brazil
• Argentina
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Please note The report will be delivered in 2-3 business days upon order notification. Show more